Spring Creek Capital’s Allergan plc AGN Stock Holding History

Spring Creek Capital’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-281,000	Closed	-$49.8M	–	31
2020 Q1	$49.8M	Buy	281,000 +81,000	+41%	+$15.3M	8%	4
2019 Q4	$38.2M	Buy	200,000 +61,000	+44%	+$11M	11.22%	2
2019 Q3	$23.4M	Sell	139,000 -11,000	-7%	-$1.79M	11.17%	3
2019 Q2	$25.1M	Buy	+150,000	New	+$20.8M	9.06%	5

Other funds holding AGN

Ashburton (Jersey) St Helier, Jersey $227M AUM

Cerebellum San Francisco, California $21.5M AUM

Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

JDC-JSC New York $20.8M AUM 30.94% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

OPS

Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return

Spring Creek Capital's AGN Position: Q2 2020 in Review

Spring Creek Capital sold out of Allergan plc (AGN) in Q2 2020, closing a stake of 281,000 shares — an estimated $49.8M sold.

Spring Creek Capital first reported a position in AGN in Q2 2019 and held it in 4 quarters. The position peaked at $49.8M in Q1 2020. 7 funds tracked by Wall St. Rank hold AGN as of Q2 2020.

Spring Creek Capital reported no remaining Allergan plc position as of Q2 2020 after selling out during the quarter.
Spring Creek Capital sold 281,000 Allergan plc shares in Q2 2020, an estimated $49.8M.
Spring Creek Capital first reported a position in Allergan plc in Q2 2019 and held it in 4 quarters.
Spring Creek Capital's Allergan plc position peaked at $49.8M in Q1 2020.
7 funds tracked by Wall St. Rank held Allergan plc as of Q2 2020.

Based on Spring Creek Capital's 13F filing for Q2 2020, filed 13 Aug 2020.